Immunotherapy News and Research

Latest Immunotherapy News and Research

Merck hosts R&D and Business Briefing

Merck & Co., Inc. today hosted its first R&D and Business Briefing since the completion of the Merck and Schering-Plough merger. The event included a comprehensive review of the company's late-stage pipeline, as well as the company's commercial strategy and progress made in the integration of Merck's worldwide operations.

12 May 2010

Updated data from Vical's Phase 2 trial of high-dose Allovectin-7 in metastatic melanoma patients

Vical Incorporated announced the publication in the June issue of Melanoma Research of updated data from the company's Phase 2 trial of high-dose (2 mg) Allovectin-7® in patients with metastatic melanoma. A separate article in the May issue of Expert Opinion on Biological Therapy reviewed results from the Phase 2 trial and previous clinical studies of Allovectin-7®.

12 May 2010

Researchers develop new type of drug to kill non-Hodgkin lymphoma tumor cells

Three researchers who are recipients of a collaborative grant from the Samuel Waxman Cancer Research Foundation have developed a new type of drug designed to kill non-Hodgkin lymphoma tumor cells. The breakthrough could lead to potential non-toxic therapies for cancer patients. The Foundation-funded investigators include Ari Melnick, M.D., of Weill Cornell Medical College, Alexander MacKerell, Ph.D., of the University of Maryland and Gilbert Priv-, Ph.D., of the University of Toronto.

11 May 2010

Dendreon reports $125.7 million net loss for first-quarter 2010

Dendreon Corporation today reported results for the quarter ended March 31, 2010. Revenue for the quarter ended March 31, 2010 was $21,000 compared to $30,000 for the quarter ended March 31, 2009.

11 May 2010

Two-day symposium on molecular neuroimaging

Today, SNM's Molecular Imaging Center of Excellence kicked off a two-day symposium bringing together individuals from multiple scientific disciplines-including chemistry, engineering, physics, molecular biology, neurosciences and imaging sciences-to promote the emerging field of molecular neuroimaging.

7 May 2010

Intellect Neurosciences signs debt settlement agreement with CARBOGEN AMCIS AG

Intellect Neurosciences, Inc., a biopharmaceutical company focused on development of disease-modifying therapeutic agents for Alzheimer's disease, announced today that it has reached a debt settlement agreement with CARBOGEN AMCIS AG, one of Intellect's largest trade creditors, in connection with prior services rendered.

6 May 2010

New research to improve effectiveness of nicotine vaccination for cigarette smokers

If Pradeep K. Garg, Ph.D., of Wake Forest University Baptist Medical Center figures out why some smokers are more addicted to nicotine than others, it could lead to more successful smoking cessation treatments.

6 May 2010

EpiCept provides update on corporate strategy, reports net loss of $4.5M for first-quarter 2010

EpiCept Corporation today announced operating and financial results for the three months ended March 31, 2010, and provided an update with respect to the Company's key business initiatives.

6 May 2010

Update on CEL-SCI's Phase III clinical trial of Multikine

CEL-SCI Corporation today provided an update on its planned Phase III clinical trial of its cancer immunotherapy drug candidate Multikine. The Company, together with its development partners Teva Pharmaceutical Industries and Orient Europharma, has already selected 40 of the planned 50 global medical centers where the Multikine Phase III study will be conducted.

6 May 2010

FDA approves Provenge for treating men with advanced prostate cancer

The US Food and Drug Administration has approved a new 'cancer vaccine' for treating men with advanced prostate cancer.

6 May 2010

Vaccinogen chooses Clinipace Worldwide to manage pivotal phase 3b confirmatory trial for OncoVAX

Clinipace Worldwide, a global full-service clinical research organization (CRO), announced today that Vaccinogen, a biotechnology company with more than three decades experience researching how to combat cancer using the body's own immune system, has selected the company to manage a pivotal phase 3b confirmatory trial for OncoVAX in the treatment of Stage II Colon Cancer.

6 May 2010

Argos Therapeutics announces presentations on sCD83 protein capabilities at 2010 American Transplant Congress

Argos Therapeutics today announced two oral presentations detailing data on its soluble CD83 (sCD83) protein program at the 2010 American Transplant Congress, held May 1-5 in San Diego. The data, which were produced by Argos in collaboration with scientists from the University of Western Ontario, demonstrate that sCD83 is capable of inducing immune system tolerance to transplant grafts and suppressing an anti-donor antibody response, via a multi-faceted mechanism-of-action that impacts B and T cells, as well as dendritic cells.

5 May 2010

Deloitte Survey: Consumers still profess to know very little about health care system in the U.S.

Following widespread media coverage of health care reform, political debates and legislative initiatives over the past year, consumers still profess to know very little about the health care system in the United States, according to the 3rd Annual Deloitte Center for Health Solutions Survey of Health Care Consumers.

5 May 2010

Additional pivotal Phase 3 trial data for MoxDuo IR released

QRxPharma announced today the release of additional pivotal Phase 3 trial data for MoxDuo IR, an immediate-release Dual-Opioid pain therapy. Required for New Drug Application submission with the United States Food and Drug Administration, this "combination rule" study compared the efficacy and safety profiles of MoxDuo IR against component doses of morphine and oxycodone alone for the management of moderate to severe post-operative pain following bunionectomy surgery.

5 May 2010

Celldex reports net loss of $6.6 million for first-quarter 2010

Celldex Therapeutics, Inc. today reported financial results for the first quarter ended March 31, 2010. Celldex reported a net loss of $6.6 million, or $0.21 per share, for the first quarter of 2010 compared to a net loss of $7.7 million, or $0.49 per share, for the first quarter of 2009. At March 31, 2010, Celldex reported cash, cash equivalents and marketable securities of $75.4 million, which the Company believes will be sufficient to meet estimated working capital requirements and fund operations into 2012.

4 May 2010

Aethlon Medical plans to initiate patient recruitment for cancer immunotherapy study

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it plans to initiate patient recruitment for a cancer immunotherapy study by year end. The pilot study seeks to demonstrate an improved immune function in cancer patients as a result of the Aethlon Hemopurifier removing tumor-secreted exosomes from the circulatory system.

4 May 2010

Novel combined immunotherapy promising for treatment of malignant brain tumors

A new Phase I clinical trial conducted at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Institute in Los Angeles shows that two innovative treatment approaches may safely be combined to treat patients with highly aggressive, malignant brain tumors called gliomas. The results suggest that combining the two therapies might boost their effectiveness and supports the pursuit of additional studies on this approach to treating these tumors.

4 May 2010

QIAGEN reports 20% revenue growth in first quarter 2010

QIAGEN N.V. today announced the results of operations for its quarter ended March 31, 2010. Net sales were at the high end of, and adjusted earnings per share for the first quarter 2010 exceeded the guidance provided by the Company on February 9, 2010.

From QIAGEN Manchester Limited 4 May 2010

Advaxis advances lead prostate cancer immunotherapeutic toward clinical trials

Advaxis, the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, is advancing the clinical development of its lead prostate cancer immunotherapeutic toward clinical trials.

3 May 2010

MannKind reports first-quarter net loss of $44.7 million applicable to common stockholders

MannKind Corporation today reported financial results for the first quarter ended March 31, 2010.

30 Apr 2010

Immunotherapy News and Research

Latest Immunotherapy News and Research

Merck hosts R&D and Business Briefing

Updated data from Vical's Phase 2 trial of high-dose Allovectin-7 in metastatic melanoma patients

Researchers develop new type of drug to kill non-Hodgkin lymphoma tumor cells

Dendreon reports $125.7 million net loss for first-quarter 2010

Two-day symposium on molecular neuroimaging

Intellect Neurosciences signs debt settlement agreement with CARBOGEN AMCIS AG

New research to improve effectiveness of nicotine vaccination for cigarette smokers

EpiCept provides update on corporate strategy, reports net loss of $4.5M for first-quarter 2010

Update on CEL-SCI's Phase III clinical trial of Multikine

FDA approves Provenge for treating men with advanced prostate cancer

Vaccinogen chooses Clinipace Worldwide to manage pivotal phase 3b confirmatory trial for OncoVAX

Argos Therapeutics announces presentations on sCD83 protein capabilities at 2010 American Transplant Congress

Deloitte Survey: Consumers still profess to know very little about health care system in the U.S.

Additional pivotal Phase 3 trial data for MoxDuo IR released

Celldex reports net loss of $6.6 million for first-quarter 2010

Aethlon Medical plans to initiate patient recruitment for cancer immunotherapy study

Novel combined immunotherapy promising for treatment of malignant brain tumors

QIAGEN reports 20% revenue growth in first quarter 2010

Advaxis advances lead prostate cancer immunotherapeutic toward clinical trials

MannKind reports first-quarter net loss of $44.7 million applicable to common stockholders

eBook: Cell-based technologies in drug discovery and Immunotherapy eBook

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Immunotherapy News and Research

Latest Immunotherapy News and Research

eBook: Cell-based technologies in drug discovery and Immunotherapy eBook

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Newsletters you may be interested in